<DOC>
	<DOCNO>NCT00960739</DOCNO>
	<brief_summary>RATIONALE : Radioactive drug , iodobenzylguanidine meta-I131 , may carry radiation directly tumor cell harm normal cell . Drugs use chemotherapy , topotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . A stem cell transplant may able replace cell destroy iodobenzylguanidine meta-i131 topotecan hydrochloride . PURPOSE : This phase II trial study side effect iodobenzylguanidine meta-I131 give together topotecan hydrochloride see well work treat young patient refractory relapse metastatic neuroblastoma .</brief_summary>
	<brief_title>Iodobenzylguanidine Meta-I131 Topotecan Young Patients With Refractory Relapsed Metastatic Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine antitumor activity iodobenzylguanidine meta-I131 ( ^131I-MIBG ) topotecan young patient refractory relapse metastatic neuroblastoma . Secondary - Determine hematological extra-hematological toxicity regimen . OUTLINE : This multicenter study . During 21 day treatment begin , autologous peripheral blood stem cell ( PBSC ) collect . Patients receive topotecan hydrochloride IV 30 minute daily day 1-5 iodobenzylguanidine meta-^131I IV 2 hour day 1 . Treatment repeat every 21 day 2 course . Patients also undergo total-body irradiation . On day 10 second course , autologous PBSC reinfused . After completion study therapy , patient follow 6 12 month .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm neuroblastoma Metastatic disease recurrent refractory induction therapy Primary metastatic tumor target MIBG fixation ( tumor/soft tissue ) &gt; 2 Autologous bone marrow peripheral blood stem cell must available WHO performance status ( PS ) 01 OR Lansky PS 70100 % Life expectancy &gt; 2 month ANC ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine clearance normal age Not pregnant nursing Fertile patient must use effective contraception No prior hypersensitivity topotecan excipients No toxicity organs ≥ NCICTCAE v3.0 grade 2 No debilitate disease No HIV positivity More 30 day since prior externalbeam radiation ( 6 week craniospinal , abdominal , pulmonary ) At least 3 week since prior chemotherapy ( 6 week mitomycin C nitrosoureas ) No contraindicated biologic therapy discontinue ≥ 4 course MIBG therapy Exclusion criterion : Pregnancy breastfeed woman HIV positive Participation another phase I , II III clinical trial Other invalidate pathology Concomitant treatment interfere MIBG Hypersensibility Topotecan</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
</DOC>